Table 1.
Baseline characteristics of COVID-19 patients with cancer stratified by the presence of comorbid CVD/CV risk factors.
| Characteristics | With CVD/CV risk factors | Without CVD/CV risk factors |
|---|---|---|
| N = 6253 | N = 4623 | |
| Demographics | ||
| Age, years [Median (IQR)] | 71 (64–79) | 53 (44–60) |
| Sex, n (%) | ||
| Female | 2815 (45) | 2953 (64) |
| Male | 3435 (55) | 1667 (36) |
| Missing/Unknown | 3 (0) | 3 (0) |
| Race, n (%) | ||
| Non-Hispanic White | 3513 (56) | 2181 (47) |
| Non-Hispanic Black | 1273 (20) | 650 (14) |
| Hispanic | 725 (12) | 1169 (25) |
| Other | 630 (10) | 547 (12) |
| Missing/Unknown | 112 (2%) | 76 (2) |
| BMI, kg/m2 [Median (IQR)] | 28.2 (24.7–32.9) | 28.0 (24.0–33.0) |
| Missing/Unknown | 1437 (23%) | 1000 (22%) |
| Cancer History | ||
| ECOG performance status prior to infection, n (%) | ||
| 0 | 1535 (25) | 1889 (41) |
| 1 | 1678 (27) | 1221 (26) |
| 2+ | 1123 (18) | 408 (9) |
| Unknown/Missing | 1917 (31) | 1105 (24) |
| Tumor Type, n (%) | ||
| Solid | 5171 (83) | 3656 (79) |
| Heme | 1340 (21) | 1081 (23) |
| Cancer Stage, n (%) | ||
| Disseminated | 1725 (28) | 1470 (32) |
| Localized | 3373 (54) | 2441 (53) |
| Missing/Unknown | 1155 (18) | 712 (15) |
| Cancer Status, n (%) | ||
| Remission/NED | 3043 (49) | 2049 (44) |
| Active, responding | 666 (11) | 656 (14) |
| Active, stable | 1093 (17) | 729 (16) |
| Active, progressing | 816 (13) | 708 (15) |
| Unknown/Missing | 635 (10%) | 481 (10) |
| Active Cancer Therapy, n (%) | ||
| None within 3 months of COVID-19 | 3673 (59) | 2229 (48) |
| Cytotoxic Therapy | 1005 (16) | 1197 (26) |
| Targeted Therapy | 793 (13) | 816 (18) |
| Endocrine Therapy | 614 (10) | 515 (11) |
| Immunotherapy | 333 (5) | 236 (5) |
| Local | 557 (9) | 450 (10) |
| Other | 95 (2) | 81 (2) |
| Missing/Unknown | 107 (2) | 60 (1) |
| Cardiac History | ||
| Cardiovascular Comorbidity, n (%) | ||
| Coronary artery disease | 1242 (20) | 0 (0) |
| Peripheral vascular disease | 290 (5) | 0 (0) |
| Cerebrovascular disease | 538 (9) | 0 (0) |
| Congestive heart failure | 783 (13) | 0 (0) |
| CV Risk Factors, n (%) | ||
| Smoker | ||
| Current | 455 (7) | 204 (4) |
| Former | 2818 (45) | 1283 (28) |
| Never | 2773 (44) | 3004 (65) |
| Missing/Unknown | 207 (3) | 132 (3) |
| Hypertension | 5061 (81) | 890 (19) |
| Hyperlipidemia | 2840 (45) | 376 (8) |
| Diabetes | 2386 (38) | 505 (11) |
| >= 2 CV risk factors | 6004 (96) | 479 (10) |
| Men ≥ 55 years old | 3373 (54) | 701 (15) |
| Women ≥ 60 years old | 2686 (43) | 653 (14) |
| Baseline Cardiac Medications, n (%) | ||
| ACE-I | 1375 (22) | 310 (7) |
| ARB | 1202 (19) | 220 (5) |
| Beta-blocker | 1797 (29) | 297 (6) |
| Statin | 3340 (53) | 506 (11) |
| AC, ASA or APT | 3352 (54) | 876 (19) |
| COVID-19 Diagnosis | ||
| Region, n (%) | ||
| US Northeast | 2132 (34) | 1344 (29) |
| US Midwest | 1908 (31) | 1094 (24) |
| US South | 939 (15) | 733 (16) |
| US West | 878 (14) | 933 (20) |
| Undesignated US | 57 (1) | 40 (1) |
| Non-US | 339 (5) | 479 (10) |
| Date of COVID-19 Diagnosis, n (%) | ||
| January–April 2020 | 694 (11) | 334 (7) |
| May–August 2020 | 2009 (32) | 1527 (33) |
| September–December 2020 | 2351 (38) | 1978 (43) |
| January–April 2021 | 405 (6) | 302 (7) |
| May–August 2021 | 362 (6) | 229 (5) |
| September–December 2021 | 424 (7) | 251 (5) |
| Missing/Unknown | 6 (0) | 1 (0) |
| COVID-19 Treatment, n (%) | ||
| HCQ only | 441 (7) | 140 (3) |
| AZT only | 577 (10) | 289 (7) |
| HCQ and AZT | 433 (7) | 199 (5) |
| Remdesivir | 1009 (17) | 446 (10) |
| Steroids | 1671 (28) | 827 (19) |
| Tocilizumab | 217 (4) | 72 (2) |
| Other | 591 (10) | 317 (7) |
ACE-I = angiotensin-converting enzyme inhibitor, AC = anticoagulation, ARB = angiotensin receptor blocker, APT = antiplatelet therapy, ASA = aspirin, AZT = azithromycin, BB = beta blocker, BMI = body mass index, CV = cardiovascular, CVD = cardiovascular disease, ECOG = Eastern Cooperative Oncology Group, HCQ = hydroxychloroquine.